Cemiplimab gained its first US approval in 2018 for use in locally advanced or metastatic cutaneous squamous cell carcinoma. Like other ICIs, and unlike HHIs, cemiplimab seeks to restimulate the ...

Figure 1: Characterization of the hybrid cell vaccine. The hybrid cell vaccination was well tolerated by all patients. There were no serious adverse effects or any clinical signs of autoimmune ...

This was repeated for an American support group for nevoid basal cell carcinoma syndrome. Because of the transient nature of these cysts, most noted that they were not significantly disturbed by ...

Basal cell carcinoma rarely metastasizes, and is usually treated by simple surgery, but it can also, in some cases, become metastatic or locally very aggressive. "That's why it's so important to ...

Treatment also includes hedgehog pathway inhibitors for metastatic basal cell carcinoma (BCC) or locally advanced BCC untreatable by local modalities or immunotherapy, specifically PD-1 inhibitors ...

which is overexpressed in > 85% of renal cell carcinomas (RCCs). We evaluated the safety and efficacy of motexafin gadolinium (MGd), a Trx inhibitor, as a single-agent therapy for metastatic RCC ...

Basal cell carcinoma occurred more frequently than squamous cell carcinoma or melanoma. More than one-quarter of blood or marrow transplant survivors developed cutaneous malignant neoplasms ...